Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 68.29

-2.0%

Nov 4 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (1041)	2/11/2008 1:50:19 PM
From: Jibacoa	Read Replies (2) of 3722

PRW was up 19.29% & is still up 14% <g> Volume of 193,107 is already > 2x its ADV bigcharts.marketwatch.com It announced that new data of 14 end-stage colorectal cancer patients from its PII on DAVANAT extended median survival > 6 months. The patients entered the trial with disease that progressed despite previously being treated with standard chemotherapies such as AVASTIN and/or ERBITUX. Two patients survived > 2Yrs. & 1 patient is still alive today. The interim data is for 14 of 20 patients who were enrolled in the trial. (The Company is in the process of gathering data on the other 6 patients.) Previous reported data from the PII for all 20 end-stage patients indicated that DAVANAT, in combination with 5-FU, extended median progression free survival to 8.4 weeks. The data also revealed a significantly reduced level of toxicity with no apparent change from the baseline measurements in any clinical parameter including platelets and white blood cell counts. Safety data indicated improved quality of life. The study objective was to treat end-stage colorectal cancer patients whose disease had progressed after receiving at least two lines of therapy that collectively included all of the following agents: 5-fluorouracil or capecitabine, irinotecan, and oxaliplatin. However, the final analysis revealed that the majority of patients also had been previously treated, and had disease progression, after therapy with AVASTIN and/or ERBITUX used in combination with chemotherapies. The insiders reportedly hold > 15% & there is poor institutional following. The stock has resistance at the $0.70 to $0.75 level before it can try to get above $1.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next